In the limited clinical trials to date, the CD27 agonizing monoclonal antibody, varlilumab, as monotherapy and with PD1/PDL1 checkpoint inhibitor therapy (nivolumab, atezolizumab), has resulted in varying degrees of objective clinical responses in a subset of cancer patients enrolled. Here, CD27 is linked to cancer.